Objective To observe the clinical effect of Qiliqiangxin Capsule combined with levosimendan injection in the treatment of elderly patients with acute myocardial infarction(AMI) and left heart failure(HF). Methods From February 2019 to September 2021, 82 patients with AMI and HF diagnosed and treated by the Second Department of Cardiovascular Disease, Affiliated Hospital of Shandong University of Traditional Chinese Medicine were randomly divided into a control group and an observation group, with 41 patients in each group. The control group was treated with levosimendan injection, and the observation group was treated with Qiliqiangxin Capsule on the basis of the control group. Observe the clinical efficacy of the two groups, the score of traditional Chinese medicine syndromes before and after treatment, cardiac color ultrasound indicators(left ventricular ejection fraction(LVEF), E/A value, left ventricular Tei index), laboratory examination indicators(partial pressure of carbon dioxide(PaCO₂), partial pressure of oxygen(PaO₂), N-terminal proBNP precursor(NT-proBNP), troponin I(cTNI), high sensitivity C-reactive protein(hs-CRP), and homocysteine level(Hcy)), The incidence of major adverse cardiovascular events(MACE) was recorded during a one-year follow-up. Results After treatment, the total effective rate of the observation group was higher than that of the control group(90.24% vs. 78.05%,χ²/P=6.104/0.047); the TCM syndrome scores of both groups(aversion to cold and cold limbs, limb edema, palpitations and shortness of breath, coldness in the waist and abdomen, difficulty urinating) were lower than before treatment, and the scores of the observation group were lower than those of the control group(t/P=2.796/0.006, 2.357/0.021, 2.015/0.047, 2.632/0.010, 2.507/0.014); LVEF and E/A values of both groups increased and left ventricular Tei index decreased after treatment, and the increase/decrease amplitude of the observation group was greater than that of the control group(t/P=3.156/0.002, 3.211/0.002, 3.604/0.001); cTNI, Hcy, NT-proBNP, hs-CRP, and PaCO₂ levels of both groups decreased, and PaO₂ increased after treatment. The levels of Hcy, NT-proBNP, hs-CRP, and PaCO₂ in the observation group were lower than those in the control group, and the PaO₂ level was higher than that in the control group(t/P=2.651/0.010, 2.872/0.005, 7.560/<0.001, 7.851/<0.001, 6.632/<0.001). there="" was="" no="" significant="" difference="" in="" ctni="" levels="" between="" the="" two="" p="">0.05); the incidence of all-cause mortality, acute fatal myocardial infarction, and acute heart failure in the observation group was lower than that in the control group(χ²/P=4.440/0.035, 3.888/0.049, 4.497/0.034).. Conclusion The clinical efficacy of Qiliqiangxin Capsule combined with levosimendan injection in the treatment of elderly patients with acute myocardial infarction and left heart failure is significant.

Myocardial infarction,acute;                    Left heart failure;                    Qiliqiangxin Capsule;                    Levosimendan injection;                    Cardiac function;                    Elderly;